1. Academic Validation
  2. PINK1-Dependent Mitophagy Inhibits Elevated Ubiquitin Phosphorylation Caused by Mitochondrial Damage

PINK1-Dependent Mitophagy Inhibits Elevated Ubiquitin Phosphorylation Caused by Mitochondrial Damage

  • J Med Chem. 2023 May 29. doi: 10.1021/acs.jmedchem.3c00555.
Olivia A Lambourne 1 Shane Bell 2 Léa P Wilhelm 3 Erika B Yarbrough 4 Gabriel G Holly 4 Oliver M Russell 2 Arwa M Alghamdi 1 Azeza M Fdel 1 Carmine Varricchio 1 Emma L Lane 1 Ian G Ganley 3 Arwyn T Jones 1 Matthew S Goldberg 4 Youcef Mehellou 1
Affiliations

Affiliations

  • 1 Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, U.K.
  • 2 Wellcome Centre for Mitochondrial Research, Newcastle University, Tyne NE2 4HH, U.K.
  • 3 MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee DD1 4HN, U.K.
  • 4 Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, The University of Alabama at Birmingham, Birmingham, Alabama 35294, United States.
Abstract

Ubiquitin phosphorylation by the mitochondrial protein kinase PTEN-induced kinase 1 (PINK1), upon mitochondrial depolarization, is an important intermediate step in the recycling of damaged mitochondria via Mitophagy. As mutations in PINK1 can cause early-onset Parkinson's disease (PD), there has been a growing interest in small-molecule activators of PINK1-mediated Mitophagy as potential PD treatments. Herein, we show that N6-substituted adenosines, such as N6-(2-furanylmethyl)adenosine (known as kinetin riboside) and N6-benzyladenosine, activate PINK1 in HeLa cells and induce PINK1-dependent Mitophagy in primary mouse fibroblasts. Interestingly, pre-treatment of HeLa cells and astrocytes with these compounds inhibited elevated ubiquitin phosphorylation that is induced by established mitochondrial depolarizing agents, carbonyl cyanide m-chlorophenyl-hydrazine and niclosamide. Together, this highlights N6-substituted adenosines as progenitor PINK1 activators that could potentially be developed, in the future, as treatments for aged and sporadic PD patients who have elevated phosphorylated ubiquitin levels in the brain.

Figures